SEC Filing - Supernus Pharmaceuticals

View:

Download DOC

Download PDF

Download XLS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 2, 2015

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
Incorporation)

001-35518		20-2590184
(Commission File Number)		(IRS Employer Identification No.)

1550 East Gude Drive, Rockville MD		20850
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (301) 838-2500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On December 2, 2015, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company’s management will be hosting investor meetings at the Guggenheim Securities 3rd Annual Boston Healthcare Conference on December 15, 2015. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

On December 4, 2015, the Company issued a press release announcing that it had received notice that, effective following the close of trading on December 3, 2015, New Enterprise Associates distributed an aggregate of 3,820,625 shares of Supernus Pharmaceuticals common stock (“common stock”) to its limited partners, and as a result no longer holds common stock in the Company. A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following documents are furnished as Exhibits pursuant to Item 8.01 hereof:

Exhibit 99.1 — Press Release Dated December 2, 2015.

Exhibit 99.2 — Press Release Dated December 4, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SUPERNUS PHARMACEUTICALS, INC.

DATED: December 7, 2015		By:	/s/ Gregory S. Patrick
		Gregory S. Patrick
		Vice-President and Chief Financial Officer

EXHIBIT INDEX

Number	Description

99.1	Press Release Dated December 2, 2015.	Attached

99.2	Press Release Dated December 4, 2015.	Attached

Exhibit 99.1

Supernus to Attend Guggenheim Securities

Boston Healthcare Conference

ROCKVILLE, Md., December 2, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company’s management will be hosting investor meetings at the Guggenheim Securities 3rd Annual Boston Healthcare Conference 2015.

Date: Tuesday, December 15, 2015
Place: The Langham, Boston

Investors interested in arranging a meeting with the Company’s management during this conference should contact the conference coordinator.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment and SPN-812 for ADHD.

CONTACT:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

Investor Contact:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

Exhibit 99.2

Supernus Announces Distribution of Common Stock by NEA

ROCKVILLE, Md., December 4, 2015 — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it has received notice that, effective following the close of trading on December 3, 2015, New Enterprise Associates (NEA) distributed an aggregate of 3,820,625 shares of Supernus Pharmaceuticals common stock to its partners, and as a result no longer holds common stock in the company. “The distribution announced today is the third and final installment of a distribution that NEA initiated earlier this year and is consistent with its customary practices. NEA distributed shares of Supernus common stock to its limited partners after holding that position for over nine years,” stated Jack Khattar, president and chief executive officer of Supernus.